Bridgene Biosciences Inc. has signed a strategic collaboration and licensing agreement with Takeda Pharmaceutical Co. Ltd. to discover small-molecule drug candidates against targets in immunology and neurology.
Researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Miramoon Pharma SL and affiliated organizations published the preclinical characterization of FKBP12 ligand MP-010 and evaluated its efficacy in models of amyotrophic lateral sclerosis.
Previous research revealed that nuclear factor of activated T cells 1 (NFAT1) is a novel regulator of the mouse double minute 2 homolog (MDM2) oncogene, which acts by directly binding to the MDM2 P2 promoter and as such, enhancing MDM2 transcription independent of p53. Researchers from the University of Houston and Baylor College of Medicine presented preclinical data for MA-242, a dual inhibitor of MDM2 and NFAT1, being developed for the treatment of cancer.
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has announced it will award US$2 million to Immunethep SA to develop a conjugated peptide-based vaccine to prevent infections from all invasive serotypes of Escherichia coli.
Researchers from Sunrock Biopharma SL presented preclinical data on SRB-1, a CCR9-depleting antibody aimed to restore immune homeostasis in patients with inflammatory bowel disease.
Researchers from Captor Therapeutics Inc. presented the preclinical characterization of CT-01, a first-in-class GSPT-1 targeted degrader under investigation for the treatment of hepatocellular carcinoma.
The most common form of hereditary deafness in humans is caused by mutations in the GJB2 gene, which encodes the gap junction protein connexin 26. That regulates the transport of potassium and metabolites between inner ear cells. The coding sequence of this gene fits in an adenovirus-associated vector (AAV), making it an attractive approach for gene therapy.
Silexion Therapeutics Corp. has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. SIL-204 is a next-generation siRNA candidate designed to target a broad range of KRAS mutations.
Kadimastem Ltd. and Itolerance Inc. have held a type B pre-IND meeting with the FDA regarding the development of ITOL-102, an investigational biologic for the treatment and potential cure of type 1 diabetes that would not require life-long chronic immune system suppression. It comprises Kadimastem’s allogenic human stem cell-derived pancreatic islets (Isletrx cells) combined with Itolerance’s immunomodulator, ITOL-100.
Patients with metastatic or unresectable gastric cancer are usually given 5-fluorouracil (5-FU) and platinum-based chemotherapy, but patients with advance disease usually have a poor prognosis. The use of chemotherapy increased the levels of cyclooxygenase-2 in tumor cells, which in turn increase the levels of prostaglandin E2 (PGE2) in the tumor microenvironment. When PGE2 binds to their receptors EP1 to EP4 on immune cells, it triggers an immunosuppressive tumor microenvironment. The use of the EP2 and EP4 dual antagonist OCT-598 was tested in the preclinical setting for gastric cancer.
RSS
